Testing effectiveness (Phase 2)Study completedNCT01217619
What this trial is testing
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
Who this might be right for
Non Small Cell Lung Cancer
Baohui Han 25